Munich - Delayed Quote EUR

Esperion Therapeutics Inc (0ET.MU)

0.8932

0.0000

(0.00%)

As of 8:00:58 AM GMT+2. Market Open.

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology and its Therapeutic Potential in Multiple Life-Threatening DiseasesANN ARBOR, Mich., April 10, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it will host an in-person R&D Day for analysts and investors on April 24, 2025, beginning at 9:00 a.m. ET in New York City. This event will feature presentations from company leadership and key opinion leaders to provide a deep dive into Esperion’s research and develop

GlobeNewswire 4 days ago

ESPR
Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound?

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 11 days ago

ESPR

SMMT
Esperion Appoints Robert E. Hoffman to Board of Directors

- Veteran Industry Executive Brings Decades of Financial and Leadership Experience - ANN ARBOR, Mich., April 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Robert E. Hoffman as an independent director, effective immediately, and he will also serve as Chairperson of the Audit Committee effective May 29, 2025. In addition, the Company announced that Nicole Vitullo and Antonio M. Gotto, Jr., M.D., D. Phil. will step down from the board of directors, effectiv

GlobeNewswire 13 days ago

ESPR
Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference

ANN ARBOR, Mich., March 24, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, at 8:45 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 day

GlobeNewswire 21 days ago

ESPR
ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia

Esperion plans to begin two phase III studies on bempedoic acid alone and in combination with ezetimibe in pediatric patients with familial hypercholesterolemia.

Zacks 24 days ago

ESPR
Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia

– Confirms Sufficient Data to Complete Phase 2 Clinical Study Enrollment and Advance to Phase 3 Studies in Both Heterozygous and Homozygous Familial Hypercholesterolemia – – Establishes Pediatric Path Forward to Start and Complete Phase 3 Trial and Secure Additional Six-Month Patent Extension Through June 2031 – ANN ARBOR, Mich., March 20, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that following meetings with the U.S. Food and Drug Administration (FDA), it has gained align

GlobeNewswire 25 days ago

ESPR
ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y

Esperion reports a narrower-than-expected loss for the fourth quarter of 2024. Revenues lag estimates. Stock up.

Zacks last month

ESPR
Q4 2024 Esperion Therapeutics Inc Earnings Call

Q4 2024 Esperion Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents last month

ESPR
Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 28.57% and 1.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

ESPR
Esperion Therapeutics: Q4 Earnings Snapshot

The Ann Arbor, Michigan-based company said it had a loss of 11 cents per share. Losses, adjusted to extinguish debt, were 10 cents per share. The results topped Wall Street expectations.

Associated Press Finance last month

ESPR
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

– FY24 Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million – –Q4 Total Revenue Grew 114% Y/Y to $69.1 Million; Q4 U.S. Net Product Revenue Grew 52% Y/Y to $31.6 Million – – Q4 Retail Prescription Equivalents Grew 45% Y/Y and 12% Q/Q – – Focused On Three Pillars for Building a Blockbuster Company: Continued Revenue Growth, Reaching Operating Profitability, and Portfolio Expansion/Pipeline Advancement – – Announces Development of Triple Combi

GlobeNewswire last month

ESPR
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with a Profitable Transfer Price on Product Sales –ANN ARBOR, Mich., March 03, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with CSL Seqirus (ASX:CSL) for the exclusive rights to commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia and New Zealand. Under the terms of the agreement, Esperion

GlobeNewswire last month

ESPR

CMXHF

CSLLY
Is Esperion Therapeutics, Inc. (ESPR) the Best Small Cap Pharma Stocks to Buy Now?

We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now. In this article, we are going to take a look at where Esperion Therapeutics, Inc. (NASDAQ:ESPR) stands against the other small cap pharma stocks. Impact of US Tariffs and Obesity Drug Performance on the Pharmaceutical Industry Emily Field, Head of […]

Insider Monkey last month

ESPR
Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Xeris Biopharma (XERS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

XERS

ESPR
Will Esperion Therapeutics (ESPR) Report Negative Earnings Next Week? What You Should Know

Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

ESPR
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Tuesday, March 4, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours aft

GlobeNewswire last month

ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on February 11, 2025, the Company granted ten new employees 58,300 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement

GlobeNewswire last month

ESPR
Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last?

Ardelyx (ARDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 2 months ago

ARDX

ESPR
Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.

– Leading Physician Expert to Discuss Continued Unmet Need in LDL-Cholesterol Management to Prevent Cardiovascular Disease – ANN ARBOR, Mich., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event to discuss the real-world use of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe). The event will be led by LeAnne Bloedon, VP, Head of Clinical Development at Esperion and will feature a discussion with: P

GlobeNewswire 3 months ago

ESPR
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference

ANN ARBOR, Mich., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 3:45 p.m. PT (6:45 p.m. ET). The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website

GlobeNewswire 3 months ago

ESPR

Performance Overview

Return	0ET.MU	S&P 500 (^GSPC)
YTD	-59.51%	-7.81%
1-Year	-60.00%	+5.83%
3-Year	-83.47%	+23.44%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Esperion Therapeutics Inc (0ET.MU)

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound?

Esperion Appoints Robert E. Hoffman to Board of Directors

Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference

ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia

Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia

ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y

Q4 2024 Esperion Therapeutics Inc Earnings Call

Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates

Esperion Therapeutics: Q4 Earnings Snapshot

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

Is Esperion Therapeutics, Inc. (ESPR) the Best Small Cap Pharma Stocks to Buy Now?

Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Will Esperion Therapeutics (ESPR) Report Negative Earnings Next Week? What You Should Know

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last?

Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.

Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference

Performance Overview